## REMARKS

Reconsideration of the rejection of this application is respectfully requested in view of the above amendments and the following remarks.

Claims 1 to 5, 9, 10, 13 to 15, 17 and 33 to 35 as amended are present.

During a telephone discussion with the Examiner, it was pointed out that in the Amendment mailed May 12, 2004, in Claim 1,  $X_x$  is defined as "a carbon chain of 1, 2, 3 or 4 carbon atoms selected from alkylene, alkenylene, allenyl or alkynylene (corrected)". In fact, each of alkylene, allenly and alkynylene have more than 1 carbon atom. Similar problems arise with the definitions of  $X_m$  and  $X_n$ .

A correction to Claim 1 was discussed, namely, to include the number of carbon atoms for each type of substituent. The Examiner suggested that a Supplemental Amendment be submitted to make the necessary corrections. It is believed that the above amendments to Claim 1 resolve all outstanding issues.

In addition, Claim 5 has been amended to narrow its scope as required in a dependent claim.

In view of the foregoing, it is believed that all objections have been overcome and that Claims 1 to 5, 9, 10, 13 to 15, 17 and 33 to 35 are in condition for allowance.

Respectfully submitted,

Bristol-Myers Squibb Company Patent Department P.O. Box 4000 Princeton, NJ 08543-4000 (609) 252-4336

Date: July 14, 7004

Burton Rodney Attorney for Applicants Reg. No. 22,076